EU Split on Covid-Patent Waivers Casts Doubt on U.S. Plan
(Bloomberg) -- Spain backed a U.S. proposal to waive intellectual property rights for coronavirus vaccines, breaking ranks with Germany and complicating efforts by the European Union to form a common stance.
“We in the Spanish government welcome Biden's proposal to suspend patents,” Spanish Prime Minister Pedro Sanchez said in Porto on Friday ahead of talks with other EU leaders. “But we think it's insufficient and that we have to be more ambitious.”
His government sent around a proposal ahead of the meeting calling for accelerating the transfer of technology for making the vaccines to all countries around the world as well as bolstering production and distribution.
Spain's position sets the stage for a tense debate over the bloc's response to the pandemic. The country is at odds with Europe's biggest economy as well as drugmakers, who warned that such a move will harm efforts to stem the pandemic.
While the head of the bloc's executive arm, Ursula von der Leyen, agreed to discuss U.S. President Joe Biden's call to waive patent protections, German Chancellor Angela Merkel dismissed it. Her health minister, Jens Spahn, said the problem is not patents but production capacity and availability, and took a swipe at Washington over its decision to block exports of Covid-19 shots.
“I would be pleased if the United States of America were prepared, just like the European Union, to release doses produced in the U.S. for export,” Spahn said Friday in Berlin. “The EU produces for the world, in the knowledge that we are only safe when everyone in the world is safe.”
French President Emmanuel Macron said on Friday that while he welcomes the debate over intellectual-property rights, he wants to protect innovation. He also prodded the U.S. and the U.K. to do more to help other countries.
“Today the Anglo-Saxons are blocking many of these ingredients and these vaccines,” he said in Porto, adding that France is working closely with Germany on the issue. “What is at stake currently isn't really intellectual property. You can give IP to labs, who don't know how to produce it and they won't produce it tomorrow.”
Waive Pharma's Vaccine Rights? What That Would Mean: QuickTake
Portugal, which holds the EU's rotating presidency, says suspending patents would be a “very important” step, but also pointed to production issues.
“We must not forget that we have a production-capacity problem and that this has to be resolved,” Augusto Santos Silva, Portugal's foreign minister, said on the sidelines of the EU leaders' summit in Porto. “That is why everyone needs to make an effort, because the supply chains of the materials needed for the production of vaccines are global.”
The split among EU members and the fierce opposition of drugmakers feed into a prolonged debate on the issue at the World Trade Organization, casting doubt on whether waivers could be deployed in time to help the fight against the pandemic. While EU leaders will discuss the matter at Friday's summit , it's unlikely that concrete decisions are imminent.
A European Commission spokeswoman told reporters in Brussels on Friday that the EU's executive arm hasn't held discussions with the Biden administration since the U.S. proposal was tabled earlier this week. The bloc first needs to define its own position and member states need to give the commission a mandate to negotiate a waiver, the spokeswoman said, adding that this is why the issue will be taken up by EU leaders at their meeting in Porto.
Read more: Countries Need Vaccines Now, and Waivers Won't Deliver Them
Officials and diplomats in Brussels cautioned that WTO deliberations will take months. Talks will also likely result only in partial waivers, as there's little chance countries such as Germany and the U.S., whose companies pioneered the development of messenger-RNA technology used in some Covid vaccines, will agree to cede intellectual property to competitors such as China.
In any case, most poor countries in the world have neither the capacity nor the expertise to produce such advanced treatments, the officials have said. EU countries are thus expected to continue lobbying the U.S. and the U.K. to allow more exports and share their stock with developing countries.
The need for vaccines is “still enormous,” Margrethe Vestager, the EU's competition commissioner, said in Porto. “That is what needs to be in focus -- so not only the patent but also the production and all the things that goes into the production for the vaccines to be delivered.”
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.